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Abstract
Background: Glutathione S-transferases (GSTs) play an important role in metabolizing anti-
epileptic drugs (AEDs) in liver. Expressions of GSTs in brain, which may result in poor efficacy of
AEDs, have not been well studied. Using clinical cortex specimen from 32 intractable epileptic
subjects and 8 non-epileptic controls, the present study investigated the correlation between GSTs
and intractable epilepsy.
Results: Three different GST isoforms (α, μ, and π) were detected with immunohistochemistry.
GST-α expression was not seen in any cortex specimens. Sixty three percent (63%) of control and
53% of intractible epileptic specimens showed GST-μ immunoreactivity. No significant difference
in intensity of GST-μ staining was observed between these two groups. GST-π expression was
found in endothelial cells and glial cells/astrocytes. Fifty percent (50%) of the control patients and
66% of the epileptic patients were GST-π positive. The grading of epileptic patients was significantly
higher than that of control patients (p < 0.01).
Conclusion: High levels of GST-π in endothelial cells and glial cells/astrocyte correlate to medical
intractable epilepsy, suggesting that GST-π contributes to resistance to AED treatment.
Background
Epilepsy is a common neurological disorder, affecting
approximately 1 to 2% of the population [1]. The major-
ity of epileptic patients are successfully treated with anti-
epileptic drugs (AEDs). Nevertheless, about 20–25% of
epileptic patients, as defined as medically intractable epi-
lepsy, fail to respond to AEDs [2].
AEDs can prevent abnormal neuronal firing and seizure
spread at seizure focus. The enzymatic activity of Glutath-
ione S-transferases (GSTs) in liver plays an essential role
in metabolizing and clearing AEDs [3-5]. GSTs are a group
of phase II enzymes of defense that catalyze the conjuga-
tion of reduced glutathione to a wide range of elec-
trophiles [6]. There are eight isoforms of soluble GST (α,
μ, π, θ, ω, ζ, σ, and κ) and at least three membrane bound
GST isoforms (MGST1, MGST2 and MGST3) [7,8]. GSTs
are widely expressed in almost every tissue, while some
isoforms show tissue-specific distribution. In mammals,
expression of GST-α, μ, and π in CNS was reported [9-12].
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of GSTs in brain, especially in brain-blood barrier may
result in poor intraparenchymal accumulation of AEDs,
and lead to medical intractability. Therefore, expression
levels of GST-α, μ, and π at cortex from intractable epilep-
tic patients were examined.
Results
Epileptic patients and their brain lesions
Thirty two (32) epileptic patients (18 male, and 14
female, aged 8 to 43 years) had been treated for over 2
years with AEDs, such as phenytoin, phenobarbital, car-
bamazepine, valproate and topiramate. Twenty-seven of
them received three drug trials, and the other five patients
received four drugs trials. The seizures attacked at least 3
times per month during the last six months. Medical
imaging and H&E staining identified structural abnormi-
ties in brains of all 32 cases. These structural brain abnor-
mities included 24 cases of hippocampal sclerosis, 5 cases
of arteriovenous malformations, 2 cases of old infarct,
and 1 case of virus encephalitis. Seizure focuses in cortex
were found in 30 cases out of 32 patients. Surgical man-
agement successfully removed epileptic associated brain
lesions and seizure focuses.
GST expression in epileptic cortex
Expression of GSTs in cortical tissues from epilepsy
patients were compared with the controls from patients
with arteriovenous malformations using immunohisto-
chemistry. GST-α was not detectible in either control spec-
imens or epileptic brain specimens. However, it was
detected in positive control specimens (hepatoma tissue).
GST-μ immunoreactivity was detected in endothelial cells
and glial cells in 63% (5/8) of control patients. The GST-
μ staining localized in cytoplasm. Fifty three percent
(53%) of epileptic patients showed GST-μ immunoreac-
tivity in endothelial cells and glial cells (Fig. 1). No signif-
icant difference in intensity of GST-μ staining was
observed between epileptic patients and controls (Table 1,
p > 0.05). GST-π immunoreactivity was detected in
endothelial cells and glial cells with a clear cytoplasmic
staining (Fig. 2A and 2B). Fifty percent (50%) of control
patients were GST-π positive, while 66% of epileptic
patients were GST-π positive. The grading of epileptic
patients was significantly higher than that of control
patients (Table 2, p < 0.01). Because all 8 the controls were
patients with arteriovenous malformations, comparison
was further made between the subgroup of 5 epileptic
patients with arteriovenous malformations and controls.
Four epileptic patients showed GST-π immunoreactivity.
The intensity of GST-π staining in glial cells was higher in
epileptic patients than that in controls (Fig. 2C and 2D),
but the grading of epileptic patients was not significantly
increased compared to that of control patients (p > 0.05).
In controls, GST-π positive glial cells showed less intensity
of GST-π staining than endothelial cells (Fig. 2E and 2F).
In epileptic group, GST-π positive cells widely distributed
in cortex and subcortex white matter. No GST-π-positive
neuron or glial cells were found in the hippocampus [Fig.
2G]. GST-π positive cells in epileptic patients showed sig-
nificant increase in immunoreactivity. The highly GST-π
GST-μ expression in epilepsy group and control groupFigure 1
GST-μ expression in epilepsy group and control group. Immunohisochemistry was performed to detect GST-μ expres-
sion in brain corex sections. GST-μ antibody primarily stains the cytoplasm of capillary endothelial cells(black arrow) and some 
glial cells(white arrow). (A) parenchymal section from epileptic patient with arteriovenous malformations (magnification ×200). 
(B) parenchymal section from control patient with arteriovenous malformations(magnification ×200).Page 2 of 5
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cytes (Fig. 2B and 2D).
Discussion
Because of the lack of response to antiepileptic drugs
(AEDs), medical intractability is a crucial clinical problem
in human epilepsy therapy. One of the most important
mechanisms of intractability is the poor penetration of
AEDs into brain. It has been shown that GST enzymatic
activity in liver plays an essential role in clearing AEDs
from blood. Expression of GSTs in brain tissue, especially
at the brain-blood barrier may provide critical role in pre-
venting AEDs from reaching seizure focus. Therefore, the
present study investigated expression patterns of GSTs in
brains of intractable epileptic patients.
Epilepsy is characterized by recurrent unprovoked sei-
zures. It starts from seizure focus, where a sudden, exces-
sive discharge of cortical neurons appear. The majority of
seizure focuses are found at cortex. In the present study,
30 out of 32 intractable epileptic patients have cortical sei-
zure focuses. To examine the role of GSTs in development
of intractability, expression of GST-α, μ, and π at seizure
focuses were investigated with immunohistochemistry,
and were compared with control normal cortex. GST-α
mainly exists in the liver, and is responsible for detoxica-
tion. In the present study, we found GST-α is not present
in brain. Though cortex expresses GST-μ, it does not cor-
relate with intractability. GST-π is expressed by cerebral
endothelial cells and glial cells. Expression of GST-π was
significantly higher in epileptic brain specimens than in
controls. Elevated GST-π in glial cells in seizure focus was
GST-π expression in epileptic group and control groupFigure 2
GST-π expression in epileptic group and control group. Immunohisochemistry was performed to detect GST-π expres-
sion in brain cortex sections with biotin streptavidin-HRP method. Endothelial cells were indicated with black arrow and glial 
cells/astrocytes were indicated with white arrow. (A, B) GST-π protein expression in temporal subcortex white matter from 
an epileptic patient with hippocampal sclerosis. Positive GST-π staining was mainly found at the cytoplasm of astrocyte-like 
cells and capillary endothelial cells (A, magnification ×100; B, magnification ×200). (C,D) GST-π protein expression in temporal 
subcortex white matter from an epileptic patient with arteriovenous malformations. Immunostaining is in the cytoplasm of 
astrocyte-like cells and capillary endothelial cells (C, magnification ×100; D, magnification ×200). (E, F) GST-π protein expres-
sion in temporal subcortex white matter from a patient of control group. Immunostaining is in capillary endothelial cells and 
some glial cells (E, magnification ×100; F, magnification ×200). (G) GST-π protein expression in brain from an epileptic patient 
with hippocampal sclerosis. Immunostaining is not detected in gyrus dentatus of hippocampus. (magnification ×100).
Table 1: Comparison of GST-μ expression between epilepsy 
group and control group
Epilepsy case (%)# Control case (%)
0 15 (46.9) 3 (37.5)
1+ 8 (25) 4 (50)
2+ 7 (21.9) 1 (12.5)
3+ 2 (6.2) 0
# p > 0.05, epilepsy vs. control
Table 2: Comparison of GST-π expression between epilepsy 
group and control group
Epilepsy case (%)* Control case (%)
0 11 (34.4) 4 (50)
1+ 2 (6.2) 4 (50)
2+ 8 (25) 0
3+ 11 (34.4) 0
* p < 0.01, epilepsy vs. controlPage 3 of 5
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typical morphology of astrocytes. Noticeably, GST-π posi-
tive astrocytes widely spread at seizure focuses. As they are
the major components of the brain-blood barrier,
endothelial cells and astrocytes directly affect the intrapa-
renchymal accumulation of AEDs. Therefore, elevated
GST-π in those cells may greatly reduce the efficacy of
AEDs. Upregulation of GST-π may be one of the key com-
ponents that contribute to intractability.
Epilepsy develops intractability with the AED treatment. It
takes various amount of time for epilepsy to become
intractable. It is still unknown how epilepsy acquires
intractability. The correlation between GST-π and intracta-
bility may suggest that epilepsy acquires the intractability
by expressing high level of GST-π in the brain. Thus, GST-
π-inducing ability could be associated with the efficacy of
AEDs. The better AEDs could be that have low GST-π-
inducing ability. Moreover, targeting GST-π may also
improve treatment outcomes in individuals with intracta-
ble epilepsy. Although some GST isoforms at liver, testis,
and brain tissues were reported to be induced by AEDs in
animal studies [13-15], the induction of GST-π by AEDs
remains to be studied.
Conclusion
High levels of GST-π in endothelial cells and glial cells/
astrocyte correlate to medical intractable epilepsy, sug-
gesting that GST-π contributes to resistance to AED treat-
ment.
Methods
Diagnosis and surgical management of medically 
intractable epilepsy
All patients took standard neuropsychological tests, ictal
and interictal electroencephalogram (EEG) recording.
Cranial magnetic resonance imaging (MRI) was per-
formed to identify primary epileptic lesions. When neces-
sary, ictal and interictal single-photon emission
computed tomography (SPECT) or positron emission
computed tomography (PET) was performed for the same
purpose. During the operation, electrocorticogram was
performed to localize seizure focuses. Epilepsy-associated
lesions and seizure focus were removed by surgery. All
procedures were approved and supervised by the Second
Affiliated Hospital Ethical Committee of Shandong Uni-
versity, and were performed with patients acknowledge-
ment and written consent.
Tissue collection and preparation
Brain specimens were obtained from 32 intractable
patients and eight control patients with arteriovenous
malformations that underwent surgical treatment. Brain
specimens were fixed with formalin and paraffin-embed-
ded. The specimens were sectioned at 5 μm.
Histology and immunohistochemistry
The pathological alterations of primary epileptic lesions
were investigated with hematoxylin and eosin (H&E)
staining and microscopy. Expression of GSTs was detected
using immunohistochemistry with HistoMark Biotin
Streptavidin-HRP Systems (Gaithersburg, Maryland,
USA). Antibodies against GST-α, μ, and π were obtained
from Lab Vision Corporation, Fremont, California, USA.
DAB was used as a chromogen. Nuclei were visualized by
hematoxylin counterstaining. Positive and negative con-
trols were included in each experiment. All sections were
processed simultaneously to ensure standard staining
conditions. All slides were examined by two pathologists
and two neurologists separately and together. To quantify,
the percentages of positively stained cells were calculated
in 5 random fields of each section of cortex. The percent-
ages were graded on a scale of 0–3+: 0, no cells stained;
1+, ≤10% of cells stained; 2+, 10–25% of cells stained; 3+,
>25% of cells stained.
Statistics
All data were analyzed with Ridit test. P < 0.05 was con-
sidered significant.
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